Evolus Inc reports results for the quarter ended June 30 - Earnings Summary

• Evolus Inc EOLS.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -4 cents. The mean expectation of seven analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -5 cents per share.

• Revenue rose 3.7% to $69.39 million from a year ago; analysts expected $82.04 million.

• Evolus Inc's reported EPS for the quarter was a loss of 27 cents​.

• The company reported a quarterly loss of $17.14 million.

• Evolus Inc shares had fallen by 1.1% this quarter and lost 17.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Evolus Inc is $23.50, about 62.1% above its last closing price of $8.91

This summary was machine generated from LSEG data August 5 at 09:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)